Opendata, web and dolomites

BLMs 4 TB SIGNED

Beta-lactams for Tuberculosis Treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BLMs 4 TB project word cloud

Explore the words cloud of the BLMs 4 TB project. It provides you a very rough idea of what is the project "BLMs 4 TB" about.

virtually    generation    molecular    modeling    extensively    barros    blms    regarded    infectious    positive    dim    pharmacokinetic    last    xdr    drug    therapy    frequency    outcome    takes    linked    garc    pharmacodynamics    data    infections    patients    tuberculosis    infected    beneficiary    killing    answer    techniques    strains    poor    treat    life    bacterial    blm    undergo    therapies    optimal    mathematical    never    antibiotics    prospects    lapse    trial    first    decades    iia    carbapenem    beta    treatment    led    adherence    point    lactams    dr    head    arose    disease    administration    cephems    tb    gsk    treatments    leads    combo    report    family    inform    track    agents    meropenem    24    pursued    worldwide    oacute    unpleasant    unclear    specificities    trials    prevent    cephalosporins    transcriptomic    renewed    quality    mdr    safest    carbapenems    market    microbiology    subset    urgently    pk    ineffective    shorten    glaxosmithkline    severe    ram    time    microscopy    longer    deadly    discontinued    record    proteomic    relapse    50    clinical    resistant    outcomes    anti    pd    validated    months    resistance    questions    hope    dosage    iacute   

Project "BLMs 4 TB" data sheet

The following table provides information about the project.

Coordinator
FUNDACION AGENCIA ARAGONESA PARA LA INVESTIGACION Y EL DESARROLLO 

Organization address
address: PASEO MARIA AGUSTIN 36 EDIFICIO PIGNATELLI PTA 30 PL 2
city: ZARAGOZA
postcode: 50004
website: www.araid.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 170˙121 €
 EC max contribution 170˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION AGENCIA ARAGONESA PARA LA INVESTIGACION Y EL DESARROLLO ES (ZARAGOZA) coordinator 170˙121.00

Map

 Project objective

Tuberculosis (TB) is the most deadly infectious disease worldwide. TB therapy takes 6 months with unpleasant side effects that leads to poor adherence and the development of drug resistance. Patients infected with multi (MDR) or extensively (XDR) drug resistant strains must undergo longer treatments (up to 24 months) associated with even severe side effects and only 30-50% positive treatment outcomes. New treatments are urgently needed.

Beta-lactams (BLMs) are the safest antibiotics in the market with a long track record of clinical use to treat bacterial infections. They were, however, traditionally regarded as ineffective for TB therapy to the point that research was virtually discontinued for the last three decades. A renewed interest recently arose after a report of Phase IIa clinical trial validated the potential of meropenem (a carbapenem). This study was led by Dr. Barros, Head TB unit GlaxoSmithKline (GSK) (the beneficiary of this proposal). In addition, Dr. Ramón-García (the applicant) just identified first-generation cephalosporins (cephems), a subset of the BLM family never pursued for TB therapy, as potential anti-TB agents. Promoting BLM development is the best immediate hope for TB patients that currently have very dim life prospects.

Carbapenems and cephems have different anti-bacterial killing properties, pharmacokinetic (PK) and pharmacodynamics (PD) parameters. These specificities affect therapy design for an optimal clinical outcome. Although promising, it is still unclear how BLMs should be included in new combo therapies (i.e. dosage, duration and frequency of administration) to shorten the duration of TB therapy, prevent relapse and treat M(X)DR-TB.

To answer these questions, I will use time-lapse microscopy linked to mathematical PK/PD modeling, transcriptomic and proteomic studies and clinical microbiology techniques to provide high quality molecular and PK/PD pre-clinical data to inform the design of future BLM TB clinical trials.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BLMS 4 TB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BLMS 4 TB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NPsVLCD (2019)

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More